BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 24, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2004

View Archived Issues

Genta highlights Q4 and full year 2003 developments

Read More

Nastech gives update on clinical development of products for obesity and sexual dysfunction

Read More

Savient reviews progress during 2003

Read More

Marcus Foundation financial commitment supports ProCord study

Read More

Bionomics files patents for genetic test for severe myoclonic epilepsy of infancy

Read More

Private equity financing to fund CellCept clinical trials for autoimmune diseases

Read More

Anticalin shows promise in vitro

Read More

Oxypurinol NDA accepted for review

Read More

Italfarmaco gains Spanish license and distribution rights to palonosetron

Read More

ThromboGenics and NuVue collaborate on plasmin products for visual disorders

Read More

Canadian approval for Factive

Read More

GSK presents four related series of ALK5 inhibitors

Read More

New porphyrin-doxorubicin conjugates prepared and tested at SLIL

Read More

Vertex claims novel GSK-3 inhibitors for stroke, Alzheimer's disease, etc.

Read More

New heparanase inhibitors and their use in angiogenesis-related conditions

Read More

New VEGFR2/VEGFR3 inhibitors identified at Schering AG

Read More

New agents for breast cancer therapy designed by Ohio State U. scientists

Read More

Novel ACAT inhibitor from Sumitomo

Read More

Potent serum HDL induction by selective PPARalpha agonist

Read More

Preliminary evidence for quinacrine in Creutzfeldt-Jakob disease

Read More

Beneficial effects of anti-IL-6R therapy in rheumatoid arthritis

Read More

Capsaicin improves ischemic threshold in stable angina patients

Read More

Effective prevention of stroke and embolism with ximelagatran after atrial fibrillation

Read More

Antithrombotic effects of DX-9065a in patients with acute coronary syndrome

Read More

Antithrombotic effects of razaxaban in healthy volunteers

Read More

Phase I trial of PPI-2458 placed on hold over animal safety data

Read More

Isis and Alnylam enter RNAi therapeutics alliance

Read More

Positive opinion in Europe for use of Glucophage in children

Read More

NDA submission for Ralivia FlashDose

Read More

Cortisol modulation license agreement finalized

Read More

Milestone achievements and patient treatment with Prolieve

Read More

Interim results from phase II Alequel study

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing